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Historically, T cell-replete myeloablative BMT from HLA-
haploidentical donors demonstrated excessive rates of
severe graft-versus-host-disease (GVHD) and non-relapse
mortality (NRM). More promising results have recently
been demonstrated for adults with high-risk hematologic
malignancies using T cell-replete marrow and post-trans-
plantation cyclophosphamide (PT/Cy). Here, we report the
ﬁrst results using such an approach speciﬁcally for pedi-
atric patients. Our single-institution phase II clinical trial
initially enrolled subjects with refractory hematologic
malignancies, but later added high risk leukemias in
remission and chemosensitive lymphomas, to match
Children's Oncology Group BMT criteria. Conditioning
consisted of IV Busulfan (pharmacokinetically adjusted)
days e6 to e3 and Cy (50 mg/kg/day) days e2 and e1
except for patients with acute lymphocytic leukemia(ALL)
or lymphoblastic lymphoma(LL) who received Cy (50 mg/
kg/day) days e5 and e4 and total body irradiation (300cGy
/day) days e3 to 0. T-cell-replete bone marrow was used
for all patients. Postgrafting immunosuppression consisted
of Cy (50 mg/kg/day) days 3 and 4, followed by myco-
phenolate mofetil for 30 days and tacrolimus for 6 months.
Twelve patients were treated with a median age of 12
(range, 2-20). Diagnoses include acute myeloid leukemia (3
refractory, 3 CR2), ALL (1 primary refractory CR1, 2 CR2), 1
chronic myeloid leukemia in blast crisis, 1 chemosensitive
LL, and 1 chemosensitive mature B cell lymphoma. Two
patients had undergone prior myeloablative allogeneic
BMTs. Donor engraftment at Day 60 occurred in all
evaluable patients. Median time to engraftment of
neutrophils >500/mL was 26 days and platelets >20,000/mL
was 35 days. Cumulative incidences of acute GVHD grades
II-IV and grades III-IV at day 100 were 17% and 7%,
respectively, and chronic GVHD at 6 months was 42% with
all classiﬁed mild per NIH cGVHD consensus criteria. One
patient required systemic steroids for Grade 3 skin aGVHD
and responded completely. The cumulative incidence of
NRM at 100 days was 8% (1/12), with one death from
veno-occlusive disease in a patient who had received
gemtuzumab ozogamicin 3 weeks before BMT. No patients
with chemosensitive disease or in remission died from
transplant-related causes. With median follow-up of
surviving patients of 276 days (range 100e1015), actuarial
overall survival (OS) is 80% at one year. Of 8 patients with
chemosensitive disease or in remission, 2 have relapsed:
one primary refractory ALL and one multi-TKI resistant Ph+
ALL. For pediatric patients with high-risk hematologic
malignancies, HLA-haploidentical BMT with T cell replete
bone marrow and PT/Cy is associated with excellent rates
of engraftment, GVHD, OS, and NRM, similar to myeloa-
blative matched sibling BMT. It is therefore a feasibleTable 1
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Recessive dystrophic epidermolysis bullosa (RDEB), an
incurable blistering genodermatosis, is due to deﬁciency of
type VII collagen (C7) resulting in lack of attachment
between the epidermis and dermis, a poor quality of life,
and early death. Between 2007 and 2012, 18 patients with
severe generalized RDEB have undergone allogeneic HCT at
the University of Minnesota. Thirteen patients were treated
with a myeloablative (MA) conditioning (busulfan IV with
pharmacokinetic targeting 1,000 mmol/min for the area
under curve; ﬂudarabine [FLU] IV 75 mg/m2, and cyclo-
phosphamide [CY] IV 200 mg/kg); 5 patients were treated
with non-MA conditioning (CY IV 50 mg/kg, FLU IV 200
mg/m2, anti-thymocyte globulin IV 90 mg/kg, and total
body irradiation 200 cGy) with cyclosporine A and myco-
phenolate mofetil as GVHD prophylaxis. Patients were
transplanted with bone marrow (BM) from an HLA-
matched sibling (n¼10) or HLA-matched unrelated donor
(n¼3), or partially matched umbilical cord blood (UCB,
n¼5). The primary endpoint of the analysis was survival
with skin improvement. Importantly, non-MA conditioning
was well tolerated, with a marked reduction in risk of
infection, and pulmonary and renal toxicity. Thus far, for
the entire cohort, the overall probability of survival is 73%
(95% CI, 49-96%) with 11 demonstrating partial to marked
biochemical and clinical improvement in mucocutaneous
disease on the basis of protein expression and resistance to
blistering. Transplant outcomes are shown in the Table 1.
We conclude that BM is the preferred source of HSC (alive
and engrafted: 11 of 13 [85%] with BM versus 1 of 5 with
CB [20%], P-value ¼ .02) and that early results with the
non-MA conditioning are promising in terms of toxicity
proﬁle and engraftment. Overall, HCT has the potential of
being a durable, systemic therapy for many people with
different forms and severities of EB, and sets the stage for
using BM cells in the treatment of a broad spectrum of
extracellular matrix disorders.ing*
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